Саркопения у пациентов с сахарным диабетом 2-го типа

Сахарный диабет и саркопения являются распространенными патологиями среди лиц пожилого и старческого возраста. По мере старения организма происходит постепенное снижение функционирующей мышечной массы, что приводит к развитию саркопении. Учитывая, что мышечная ткань играет немаловажную роль в гомеостазе глюкозы, это обстоятельство непременно сказывается и на течении сахарного диабета. Цель обзора: подробно описать патогенетические взаимодействия двух возраст-ассоциированных заболеваний — саркопении и сахарного диабета 2-го типа. Понимание общности патогенеза даст возможность разобраться в течении обоих заболеваний и определить тактику ведения данных пациентов, что в свою очередь позволит замедлить их прогрессирование, достичь и реализовать концепцию активного, здорового старения, продлить период высокой физической, а также функциональной активности.

1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М. 2023 DOI: 10.14341/DM13042

2. Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4–13. DOI: 10.26442/00403660.2019.10.000364

3. Izzo A., Massimino E., Riccardi G. et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. DOI: 10.3390/nu13010183

4. Liccini A., Malmstrom T.K. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J. Am. Med. Dir. Assoc. 2016;17(9):846–851. DOI: 10.1016/j.jamda.2016.07.007

5. Kawada T. Mortality risk of sarcopenia in older subjects. J. Am. Med. Dir. Assoc. 2021;22(9):1883. DOI: 10.1016/j.jamda.2021.04.011.

6. Xu J., Wan C.S., Ktoris K. et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361–376. DOI: 10.1159/000517099

7. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on defi nition and diagnosis - Report of the European working group on Sarcopenia in older people. Age Ageing. 2010;39:412–423. DOI: 10.1093/ageing/afq034

8. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2.

9. Аметов А.С., Пуговкина Я.В. Гомеостаз глюкозы и метаболическая гибкость у здоровых людей. Эндокринология: новости, мнения, обучение. 2020;9(4):12–22. DOI: 10.33029/2304-9529-2020-9-4-12-22

10. Mesinovic J., Zengin A., De Courten B., Ebeling P.R. and Scott D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab. Syndr. Obes. 2019;12:1057–1072. DOI: 10.2147/DMSO.S186600

11. Rizvi A.A., Rizzo M. Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults. Medicina (Kaunas). 2024;60(10):1648. DOI: 10.3390/medicina60101648.

12. Wu H., Liu M., Chi V.T.Q. et al. Handgrip strength is inversely associated with metabolic syndrome and its separate components in middle aged and older adults: a large-scale population-based study. Metabolism. 2019;93:61–67.

13. Zamboni M., Gattazzo S., Rossi A.P. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur. Geriatr. Med. 2019;10(1):5–6. DOI: 10.1007/s41999-018-0134-3

14. Тополянская С.В. Жировая ткань и лептин при старении. Клиническая геронтология. 2020; 26 (7-8): 57-63. DOI: 10.26347/1607- 2499202007-08057-063.

15. Mitchell W.K., Williams J., Atherton P. et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. DOI: 10.3389/fphys.2012.00260

16. Cretoiu D., Pavelescu L., Duica F., Radu M., Suciu N., Cretoiu S.M. Myofi bers. Adv. Exp. Med. Biol. 2018;1088:23–46. DOI: 10.1007/978-981-13-1435-3_2.

17. Coelho-Junior H.J., Picca A., Calvani, R., Uchida M.C., Marzetti E. If my muscle could talk: Myokines as a biomarker of frailty. Exp. Gerontol. 2019;127:110715 DOI: 10.1016/j.exger.2019.110715

18. Briana D.D., Malamitsi-Puchner A. Developmental origins of adult health and disease: The metabolic role of BDNF from early life to adulthood. Metabolism. 2018;81:45–51. DOI: 10.1016/j.metabol.2017.11.019

19. Levy M.J.F., Boulle F., Steinbusch H.W., van den Hove D.L.A., Kenis G., Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. 2018;235:2195–2220. DOI: 10.1007/s00213-018-4950-4

20. Chen W., Wang L., You W., Shan T. Myokines mediate the cross talk between skeletal muscle and other organs. J. Cell. Physiol. 2021;236:2393–2412. DOI: 10.1002/jcp.30033:

21. Wacker M., Holick MF. Vitamin D-eff ects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111–48. DOI: 10.3390/nu5010111

22. Wintermeyer E., Ihle C., Ehnert S., Stöckle U., Ochs G., De Zwart P. et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8(6):319. DOI: 10.3390/nu8060319

23. Oshiro CE., Hillier TA., Edmonds G., Peterson M., Hill PL, Hampson S. Vitamin D defi ciency and insuffi ciency in Hawaii: levels and sources of serum vitamin D in older adults. Am. J. Hum. Biol. 2022;34(3):e23636. DOI: 10.1002/ajhb.23636

24. Gallagher J.C. Vitamin D and aging. Endocr. Metab. Clin. 2013;42(2):319–32. DOI: 10.1016/j.ecl.2013.02.004.

25. Uchitomi R., Oyabu M., Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12(10):3189. DOI: 10.3390/nu12103189

26. Remelli F., Vitali A., Zurlo A. et al. Vitamin D defi ciency and sarcopenia in older persons. Nutrients. 2019;11(12):2861. DOI: 10.3390/nu11122861

27. Kalyani R.R., Metter E.J., Egan J. et al. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care. 2015;38(1):82–90. DOI: 10.2337/dc14-1166

28. Yaribeygi H., Farrokhi F.R., Butler A.E. et al. Insulin resistance: review of the underlying molecular mechanisms. J. Cell. Physiol. 2019;234(6):8152–8161. DOI: 10.1002/jcp.27603

29. Liu Z.J., Zhu C.F. Causal relationship between insulin resistance and sarcopenia. Diabetol. Metab. Syndr. 2023;15(1):46. DOI: 10.1186/s13098-023-01022-z.

30. Giha H.A., Alamin O.A.O., Sater M.S. Diabetic sarcopenia: metabolic and molecular appraisal. Acta Diabetol. 2022;59(8):989– 1000. DOI: 10.1007/s00592-022-01883-2

31. Goossens G.H., Blaak E.E., Theunissen R. et al. Expression of NLRP3 infl ammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 2012;50(3):142–149. DOI: 10.1016/j.molimm.2012.01.005

32. Mcbride M.J., Foley K.P., D’souza D.M. et al. The NLRP3 infl ammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 2017;313(2):E222– E232. DOI: 10.1152/ajpendo.00060.2017

33. Shimizu N. et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell. Metab. 2011;13(2):170–182. DOI: 10.1016/j.cmet.2011.01.001.

34. Hirata Y., Nomura K., Senga Y., Okada Y., Kobayashi K., Okamoto S., Minokoshi Y., Imamura M., Takeda S., Hosooka T., Ogawa W. Hyperglycemia induces skeletal muscle atrophy via a WWP1/ KLF15 axis. JCI Insight. 2019;4(4):e124952. DOI: 10.1172/jci.insight.124952.

35. Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J. Hepatol. 2016;65(6):1232–1244. DOI: 10.1016/j.jhep.2016.07.040

36. Yoshida T., Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. DOI: 10.3390/cells9091970

37. Bassil M.S., Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr. Opin. Clin. Nutr. Metab. Care. 2013;16(1):83–88. DOI: 10.1097/MCO.0b013e32835a88ee

38. Kalyani R.R., Corriere M., Ferrucci L. Age-related and diseaserelated muscle loss: the eff ect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–829. DOI: 10.1016/S2213-8587(14)70034-8

39. Qiu J., Thapaliya S., Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc. Natl. Acad. Sci. USA. 2013;110(45):18162–18167. DOI: 10.1073/pnas.1317049110

40. Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014;10(9):504–516. DOI: 10.1038/nrneph.2014.112

41. Bataille S., Chauveau P., Fouque D. et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol. Dial. Transplant. 2021;36(11):1986–1993. DOI: 10.1093/ndt/gfaa129

42. Baczek J., Silkiewicz M., Wojszel Z.B. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12(8):2401. DOI: 10.3390/nu12082401

43. Donath M.Y., Shoelson S.E. Type 2 diabetes as an infl ammatory disease. Nat. Rev. Immunol. 2011;11(2):98–107. DOI: 10.1038/nri2925

44. Perry B.D., Caldow M.K., Brennan-Speranza T.C. et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of infl ammatory pathways, physical activity and exercise. Exerc. Immunol. Rev. 2016;22:94–109 PMID: 26859514; PMCID: PMC5545118

45. Zhang X., Li H., He M. et al. Immune system and sarcopenia: presented relationship and future perspective. Exp. Gerontol. 2022;164:111823. DOI: 10.1016/j.exger.2022.111823

46. Goyal R., Faizy A.F., Siddiqui S.S. et al. Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin eff ects. N. Am. J. Med. Sci. 2012;4(4):180–184. DOI: 10.4103/1947-2714.94944

47. Omura T., Araki A. Skeletal muscle as a treatment target for older adults with diabetes mellitus: the importance of a multimodal intervention based on functional category. Geriatr Gerontol. Int. 2022;22(2):110–120. DOI: 10.1111/ggi.14339

48. Bowen T.S., Schuler G., Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle. 2015;6(3):197– 207. DOI: 10.1002/jcsm.12043

49. Hyatt H.W., Powers S.K. The role of calpains in skeletal muscle remodeling with exercise and inactivity-induced atrophy. Int. J. Sports Med. 2020;41(14):994–1008. DOI: 10.1055/a-1199-7662

50. Huang J., Zhu X. The molecular mechanisms of calpains action on skeletal muscle atrophy. Physiol. Res. 2016;65(4):547–560. DOI: 10.33549/physiolres.933087

51. Suzuki A., Yabu A., Nakamura H. Advanced glycation end products in musculoskeletal system and disorders. Methods. 2022;203:179– 186. DOI: 10.1016/j.ymeth.2020.09.012

52. Forbes J.M., Sourris K.C., De Courten M.P. et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids. 2014;46(2):321–326. DOI: 10.1007/s00726-013-1542-9

53. Cleasby M.E., Jamieson P.M. Atherton P.J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J. Endocrinol. 2016;229(2):R67–81. DOI: 10.1530/JOE-15-0533

54. Jimenez-Gutierrez G.E., Martínez-Gómez L.E., Martínez-Armenta C. et al. Molecular mechanisms of infl ammation in sarcopenia: diagnosis and therapeutic update. Cells. 2022;11(15):2359. DOI: 10.3390/cells11152359

55. Csapo R., Malis V., Sinha U. et al. Age-associated diff erences in triceps surae muscle composition and strength - an MRI-based crosssectional comparison of contractile, adipose and connective tissue. BMC Musculoskelet Disord. 2014;15:209. DOI: 10.1186/1471-2474-15-209.